R&G PharmaStudies Future Growth
Future criteria checks 4/6
R&G PharmaStudies is forecast to grow earnings and revenue by 27% and 18.1% per annum respectively. EPS is expected to grow by 22.8% per annum. Return on equity is forecast to be 10.3% in 3 years.
Key information
27.0%
Earnings growth rate
22.8%
EPS growth rate
| Life Sciences earnings growth | 32.9% |
| Revenue growth rate | 18.1% |
| Future return on equity | 10.3% |
| Analyst coverage | Low |
| Last updated | 19 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,130 | 234 | N/A | 241 | 2 |
| 12/31/2025 | 982 | 205 | N/A | 210 | 4 |
| 12/31/2024 | 811 | 162 | N/A | 148 | 3 |
| 9/30/2024 | 759 | 121 | 152 | 169 | N/A |
| 6/30/2024 | 738 | 135 | 194 | 211 | N/A |
| 3/31/2024 | 738 | 157 | 177 | 198 | N/A |
| 12/31/2023 | 721 | 163 | 173 | 193 | N/A |
| 9/30/2023 | 694 | 155 | 175 | 197 | N/A |
| 6/30/2023 | 673 | 138 | 106 | 128 | N/A |
| 3/31/2023 | 628 | 115 | 126 | 144 | N/A |
| 1/1/2023 | 638 | 113 | 110 | 130 | N/A |
| 9/30/2022 | 634 | 112 | 121 | 154 | N/A |
| 6/30/2022 | 640 | 110 | 93 | 127 | N/A |
| 3/31/2022 | 632 | 101 | 66 | 102 | N/A |
| 1/1/2022 | 608 | 99 | 76 | 115 | N/A |
| 12/31/2020 | 484 | 84 | 19 | 44 | N/A |
| 12/31/2019 | 425 | 83 | 77 | 103 | N/A |
| 12/31/2015 | 142 | 24 | N/A | 17 | N/A |
| 12/31/2014 | 96 | 14 | N/A | 24 | N/A |
| 12/31/2013 | 78 | 12 | N/A | 10 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 301333's forecast earnings growth (27% per year) is above the savings rate (2.8%).
Earnings vs Market: 301333's earnings (27% per year) are forecast to grow faster than the CN market (26.2% per year).
High Growth Earnings: 301333's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 301333's revenue (18.1% per year) is forecast to grow faster than the CN market (13.8% per year).
High Growth Revenue: 301333's revenue (18.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 301333's Return on Equity is forecast to be low in 3 years time (10.3%).